European Hematology Association: Update on bb2121, a Promising Therapy for Patients with Heavily Pre-treated Relapsed/Refractory Multiple Myeloma

USA - English

• USA - Français
• USA - español
• USA - Deutsch

STOCKHOLM, June 15, 2018 /PRNewswire/ --

The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated results from 43 patients after five more months of follow-up show that bb2121 remains generally well-tolerated while inducing deep and durable responses in patients with advanced MM. The median PFS among 18 patients treated with active doses in the dose escalation cohort was 11.8 months and a 96% ORR was reported in 22 patients treated with >150 × 106 CAR T cells. Additionally, an unprecedented rate of MRD negativity was observed, with 100% of 16 evaluable responders achieving MRD negativity. Comparable activity was observed in patients with low (<50%) versus high (≥50%) BCMA-expressing myeloma (ORR of 100% vs 91%, respectively). Results from this ongoing study are informing the global pivotal phase II trial (KarMMaTM) in patients with relapsed and refractory MM, which is now open for enrollment in North America and Europe.

     (Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )

Presenter: Dr Jesús Berdeja

Affiliation:  Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA

Topic: BB2121 ANTI-BCMA CAR T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM A MULTICENTER PHASE I STUDY

Abstract S138 will be presented by Jesús Berdeja on Friday, June 15, 12:30-12:45 in Room A8.

About the EHA Annual Congress
Every year in June, EHA organizes its Annual Congress in a major European city. After five years, the congress returns to Stockholm. The Congress is aimed at health professionals working in or interested in the field of hematology.

The scientific program topics range from stem cell physiology and development, to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders as well as transfusion and stem cell transplantation.

Embargo

Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here. Are you interested in the program of the 23^rd Congress? This can be found here.

Website: www.ehaweb.org

SOURCE European Hematology Association